Gamida Cell Announces First Patient Transplanted in Phase 1/2 Study of CordIn for Severe Aplastic Anemia and Hypoplastic MDS

August 21, 2017 — The first subject has been transplanted in an investigator-initiated study of Cordin™ for patients with severe aplastic anemia (AA) or hypoplastic myelodysplastic syndrome (MDS) who have no available matched donor. CordIn™ is produced by Jerusalem based Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases.

CordIn™ is in development for patients with rare genetic diseases where bone marrow transplantation is clinically established as a potential cure but no fully matched donors are available. CordIn™ is also currently being evaluated in a Phase 1/2 study in patients with sickle cell disease, a rare genetic disease of red blood cells.

For more information, see:  http://www.gamida-cell.com/press_release/gamida-cell-announces-first-patient-transplanted-in-phase-12-study-of-cordin-for-severe-aplastic-anemia-and-hypoplastic-mds/

Show Buttons
Share On Facebook
Share On Twitter
Share On Google Plus
Share On Linkedin
Hide Buttons